CD19 and congenital rubella syndrome: Despite the transforming revolution seen with anti-CD19 CAR T-cell therapy, with response rates up to 40% compared to 10% with standard chemotherapies in the relapsed/refractory disease setting, adverse events such as ICANS (immune effector cell-associated neurotoxicity syndrome) and CRS (cytokine release syndrome) with CAR T-cell therapy raises concerns, calling for strategies to mitigate them [81].